Molecule News and Research

RSS

AHA to honor BIDMC investigator for groundbreaking Vascular Biology research

Alterations in blood vessel dilation lie at the heart of coronary artery health: When vessels dilate, blood and oxygen supplies successfully reach the heart. When vessels contract, blood and oxygen are diminished, leading to coronary artery disease.

23 Mar 2011

Researchers discover novel gene regulation mechanism that contributes to HCC development

Researchers at Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine have discovered a novel mechanism in gene regulation that contributes to the development of a form of liver cancer called hepatocellular carcinoma.

23 Mar 2011

Scientists create organic nanoparticle to treat cancer and deliver drugs

A team of scientists from Princess Margaret Hospital have created an organic nanoparticle that is completely non-toxic, biodegradable and nimble in the way it uses light and heat to treat cancer and deliver drugs.

22 Mar 2011

Oral desensitization with omalizumab may treat milk allergy in children

Some 3 million children in the United States have some form of food allergy, ranging in severity from mild to life-threatening. Milk allergy is the most common, affecting 2.5 percent of children under age 3.

22 Mar 2011

Second US trial in HIV/AIDS lymphoma patients using Benitec’s ddRNAi technology

Benitec Limited (ASX:BLT), a company involved in RNA-based gene silencing for human therapeutics, announced that the City of Hope research hospital in Duarte, California is planning to initiate a second small Phase I/II study using Benitec’s DNA-directed RNA interference (ddRNAi) technology in lymphoma patients carrying the HIV virus. The aim of the study is to optimize the treatment by modifying a range of clinical parameters.

21 Mar 2011

ADDF awards ADispell 170,750 grant to develop drugs against Alzheimer's Disease

The Alzheimer's Drug Discovery Foundation (ADDF) announced that it has awarded a grant of $170,750 to ADispell Inc. to develop small molecule drugs designed to halt the progression of cognition loss that occurs with Alzheimer's Disease.

21 Mar 2011

Study unravels molecular mechanism of biomolecule RNA that plays dynamic regulatory role in protein selection

If a big bunch of your brain cells suddenly went rogue and decided to become fat cells, it could cloud your decision-making capacity a bit. Fortunately, early in an organism's development, cells make firm and more-or-less permanent decisions about whether they will live their lives as, say, skin cells, brain cells or, well, fat cells.

21 Mar 2011

Organic, non-toxic, biodegradable nanoparticle uses light and heat to treat cancer

21 Mar 2011

More opportunities to develop therapies for protein misfolding

Romping clumps of misfolded proteins are prime suspects in many neurological disorders including Alzheimer's, Parkinson's, and Creutzfeld-Jakob Disease. Those diseases are devastating and incurable, but a team of biologists at Brown University reports that cells can fix the problems themselves with only a little bit of help. The insight suggests that there are more opportunities to develop a therapy for protein misfolding than scientists had thought.

21 Mar 2011

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced a positive outcome from a pivotal Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class hedgehog pathway inhibitor, in patients with advanced basal cell carcinoma (BCC).

21 Mar 2011

New insight into Duchenne muscular dystrophy

Armed with a zebrafish model of Duchenne muscular dystrophy and a library of 1,200 chemicals already approved for human use, researchers at Children's Hospital Boston have identified a compound that reverses the loss of muscle structure and function associated with DMD, seemingly by compensating for the loss of a critical protein.

19 Mar 2011

Researchers identify protein that triggers immune response in TB-infected people

Scientists have discovered a protein secreted by tuberculosis bacteria that could be a promising new vaccine candidate, they report today in Proceedings of the National Academy of Sciences. The protein could also be used to improve diagnosis of TB.

19 Mar 2011

Celera reports net revenue of $34.9 million for fourth quarter of 2010

Celera Corporation today reported net revenues of $34.9 million for the fourth quarter of 2010 that ended December 25, 2010, compared to $39.2 million for the prior year quarter.

18 Mar 2011

Science journal publishes CYTK preclinical cardiac myosin activation research results

Cytokinetics, Incorporated announced today the publication of preclinical research in the March 18, 2011 issue of the journal Science regarding the activation of cardiac myosin by an investigational drug candidate, omecamtiv mecarbil, and the potential therapeutic role that this novel mechanism may play for patients with systolic heart failure.

18 Mar 2011

BUSM scientists identify new biomarker and melanoma treatment target

Researchers at Boston University School of Medicine, in collaboration with Johns Hopkins University, have identified a potential new biomarker and therapeutic target for melanoma.

18 Mar 2011

AICR awards £179,532 grant to Van Andel Research Institute for prostate cancer research

Research by scientists in America, funded by an international charity based in Scotland, could lead to new drugs for prostate cancer.

17 Mar 2011

Low calorie diet may delay or prevent aging and neurodegenerative diseases

Cells, which employ a process called autophagy to clean up and reuse protein debris leftover from biological processes, were the original recyclers. A team of scientists from Paul Greengard's Rockefeller University laboratory have linked a molecule that stimulates autophagy with the reduction of one of Alzheimer's disease's major hallmarks, amyloid peptide.

17 Mar 2011

PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting

PsiOxus Therapeutics, Ltd. announced initiation of a Phase II study of MT-102, a small molecule therapeutic for the treatment of cancer- and age-related wasting. MT-102 is being developed to reverse the effects of cachexia, a wasting disease that accompanies cancer, heart failure, COPD, renal failure, cirrhosis and rheumatoid arthritis, and that is associated with significant morbidity and mortality.

17 Mar 2011

Oxford Nanopore selects Accelrys Pipeline Pilot NGS Collection as preferred analysis platform

Accelrys, Inc., a leading scientific enterprise R&D software and services company, today announced the signing of a partnership agreement with Oxford Nanopore Technologies Ltd. Under the terms of the partnership, Accelrys and Oxford Nanopore will develop software to enable complex, real-time analyses of experimental data produced by the Oxford Nanopore single molecule analysis system.

From Oxford Nanopore Technologies 16 Mar 2011

Scientists create new drug delivery system to treat cancer

Scientists in Syracuse University's Chemistry Department have created a new drug delivery system expected to advance the effectiveness of cancer-killing drugs. It uses gold nanoparticles with attached DNA that binds to a proven anti-cancer drug, Doxorubicin or DOX.

16 Mar 2011

Molecule News and Research

AHA to honor BIDMC investigator for groundbreaking Vascular Biology research

Researchers discover novel gene regulation mechanism that contributes to HCC development

Scientists create organic nanoparticle to treat cancer and deliver drugs

Oral desensitization with omalizumab may treat milk allergy in children

Second US trial in HIV/AIDS lymphoma patients using Benitec’s ddRNAi technology

ADDF awards ADispell 170,750 grant to develop drugs against Alzheimer's Disease

Study unravels molecular mechanism of biomolecule RNA that plays dynamic regulatory role in protein selection

Organic, non-toxic, biodegradable nanoparticle uses light and heat to treat cancer

More opportunities to develop therapies for protein misfolding

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

New insight into Duchenne muscular dystrophy

Researchers identify protein that triggers immune response in TB-infected people

Celera reports net revenue of $34.9 million for fourth quarter of 2010

Science journal publishes CYTK preclinical cardiac myosin activation research results

BUSM scientists identify new biomarker and melanoma treatment target

AICR awards £179,532 grant to Van Andel Research Institute for prostate cancer research

Low calorie diet may delay or prevent aging and neurodegenerative diseases

PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting

Oxford Nanopore selects Accelrys Pipeline Pilot NGS Collection as preferred analysis platform

Scientists create new drug delivery system to treat cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News